Bristol Myers Squibb Press Releases https://bristolmyers2016ir.q4web.com/generated by Q4Tue, 27 Oct 2026 06:18:56 -0400Copyright Q4 Inc. All rights reserved.Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study81d62c2e-b46a-4eda-85b3-69e9e0596ff0https://bristolmyers2016ir.q4web.com/iframes/press-releases/press-release-details/2026/Izalontamab-Brengitecan-Iza-Bren-Doubles-Median-Progression-Free-Survival-in-Patients-with-Previously-Treated-EGFR-Mutated-Non-Small-Cell-Lung-Cancer-Compared-to-Chemotherapy-in-the-Phase-3-PANKU-Lung01-Study/default.aspxMon, 26 Oct 2026 03:30:00 -0400BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy26483a5d-8655-40cd-b146-5450f71e4507https://bristolmyers2016ir.q4web.com/iframes/press-releases/press-release-details/2026/BioNTech-and-Bristol-Myers-Squibb-Report-Encouraging-Global-Phase-2-data-for-Pumitamig-in-Advanced-NSCLC-After-Progression-on-Immunotherapy-Plus-Chemotherapy/default.aspxSun, 25 Oct 2026 03:30:00 -0400Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients with Highly Active Relapsing and Progressive Forms of Multiple Sclerosis at MSToronto 2026a26923e9-c6f2-4ca2-a502-8b00bd781adchttps://bristolmyers2016ir.q4web.com/iframes/press-releases/press-release-details/2026/Bristol-Myers-Squibb-Presents-Results-from-Phase-1-Breakfree-2-Study-of-Zolacabtagene-Autoleucel-BMS-986353-in-Patients-with-Highly-Active-Relapsing-and-Progressive-Forms-of-Multiple-Sclerosis-at-MSToronto-2026/default.aspxFri, 23 Oct 2026 10:30:00 -0400Izalontamab Brengitecan (Iza-Bren) Reduced Risk of Disease Progression or Death by 59% versus Chemotherapy in Patients with Advanced HR+/HER2- Breast Cancer in Phase 3 PANKU-Breast01 Studyccd8fd5e-3eb8-4618-8a67-d82bf4038d52https://bristolmyers2016ir.q4web.com/iframes/press-releases/press-release-details/2026/Izalontamab-Brengitecan-Iza-Bren-Reduced-Risk-of-Disease-Progression-or-Death-by-59-versus-Chemotherapy-in-Patients-with-Advanced-HRHER2--Breast-Cancer-in-Phase-3-PANKU-Breast01-Study/default.aspxFri, 23 Oct 2026 07:30:00 -0400Bristol Myers Squibb to Showcase Next-Generation Cancer Modalities and Leadership Across Solid Tumors at ESMO 20261f10c61d-0e23-4c07-b28a-8d8e3c9792aehttps://bristolmyers2016ir.q4web.com/iframes/press-releases/press-release-details/2026/Bristol-Myers-Squibb-to-Showcase-Next-Generation-Cancer-Modalities-and-Leadership-Across-Solid-Tumors-at-ESMO-2026/default.aspxMon, 19 Oct 2026 06:59:00 -0400Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio’s Radiopharmaceutical Therapy, in Patients with GEP-NETs3d45d842-85a0-4d1d-8414-90a1d6a366cfhttps://bristolmyers2016ir.q4web.com/iframes/press-releases/press-release-details/2026/Bristol-Myers-Squibb-Announces-Positive-Topline-Results-from-the-Interim-Analysis-of-Phase-3-ACTION-1-for-RYZ101-RayzeBios-Radiopharmaceutical-Therapy-in-Patients-with-GEP-NETs/default.aspxMon, 12 Oct 2026 06:55:00 -0400Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpointb762fa3b-53da-4701-ac36-9a021f566a72https://bristolmyers2016ir.q4web.com/iframes/press-releases/press-release-details/2026/Bristol-Myers-Squibb-Announces-Phase-3-ALOFT-IPF-Trial-Evaluating-Admilparant-in-Adults-with-Idiopathic-Pulmonary-Fibrosis-Met-Primary-Endpoint/default.aspxMon, 12 Oct 2026 06:50:00 -0400Bristol Myers Squibb Announces ZENBEXUS (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs. Standard of Care in Relapsed and Refractory Multiple Myeloma in Phase 3...3c708ffa-a939-4690-8e0e-18cf21b4e66bhttps://bristolmyers2016ir.q4web.com/iframes/press-releases/press-release-details/2026/Bristol-Myers-Squibb-Announces-ZENBEXUSTM-iberdomide-in-Combination-with-Daratumumab-and-Dexamethasone-ZDd-Demonstrates-Superior-Progression-Free-Survival-vs--Standard-of-Care-in-Relapsed-and-Refractory-Multiple-Myeloma-in-Phase-3---/default.aspxThu, 08 Oct 2026 06:59:00 -0400Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movementfd8faa1f-f6bb-4fbe-8c78-b94f1cec0916https://bristolmyers2016ir.q4web.com/iframes/press-releases/press-release-details/2026/Bristol-Myers-Squibb-Deepens-Commitment-to-Healthcare-Professionals-Through-Champions-in-Care-Movement/default.aspxThu, 01 Oct 2026 06:59:00 -0400U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb’s CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients*fa9bc678-3191-40eb-be52-4a8cd8865e28https://bristolmyers2016ir.q4web.com/iframes/press-releases/press-release-details/2026/U-S--Food-and-Drug-Administration-Approves-Expanded-Indication-for-Bristol-Myers-Squibbs-CAMZYOS-mavacamten-for-the-Treatment-of-Symptomatic-Obstructive-Hypertrophic-Cardiomyopathy-oHCM-in-Adults-and-Pediatric-Patients/default.aspxWed, 30 Sep 2026 17:32:00 -0400